Revolutionizing treatment for recurrent glioblastoma with intraventricular CARv3-TEAM-E T cells
Notice bibliographique
Résumé
Dear Editor, Glioblastoma remains one of the most daunting challenges in neuro-oncology, notorious for its poor prognosis and limited treatment options1. It is characterized by its aggressive growth and recurrence, often leading to a median survival of just over a year with current therapies2. A recent study has shown the use of intraventricular CARv3-TEAM-E T cells, a form of immunotherapy that targets cancer cells with remarkable precision3. The study focuses on a new variant of chimeric antigen receptor (CAR) T cell therapy, specifically engineered to target EGFRvIII, a common mutation in glioblastoma cells3. Unlike traditional treatments, which often fail to selectively target tumor cells and spare normal brain tissue, CARv3-TEAM-E T cells are designed to recognize and destroy only the cancer cells, minimizing damage to surrounding healthy cells. This early phase 1 study included three patients with recurrent glioblastoma, who had exhausted other treatment options, received intraventricular infusions of CARv3-TEAM-E T cells3. A single infusion of CARv3-TEAM-E T cells, led to rapid regression of the tumor, confirmed radiologically using MRI scans. Tumor regression was transient in two patients, and one of the patients had durable regression during the short term follow-up. Also, the treatment was well-tolerated, with manageable side effects compared to the often-debilitating consequences of conventional chemotherapy and radiation. One of the patients died due to gastrointestinal perforation, which was not attributed to CARv3-TEAM-E T cell infusion. The rest of the two patients developed pulmonary nodules and ground glass opacities, which were transient and resolved by 4–6 weeks. This groundbreaking therapy could potentially redefine the landscape of treatment for recurrent glioblastoma, offering new hope to patients battling this aggressive cancer. First and foremost, this therapy offers a lifeline to patients with recurrent glioblastoma, potentially increasing survival times and improving quality of life. Moreover, the success of intraventricular administration suggests that similar approaches could be developed for other types of brain tumors, potentially ushering in a new era of cancer treatment. By investigating specific genetic markers, treatments can be tailored to individual patients, enhancing efficacy and reducing unwanted side effects. This personalized approach to cancer treatment is at the forefront of oncological research and could lead to more successful outcomes across a spectrum of cancers4. However, the path forward is not without challenges. The complexity and cost of developing and administering CAR T cell therapies may limit accessibility for many patients, particularly in less developed healthcare systems. Furthermore, as with any new treatment, long-term effects and effectiveness in a broader population remain to be evaluated in phase 2 and phase 3 clinical trials. In conclusion, the development of intraventricular CARv3-TEAM-E T cells for the treatment of recurrent glioblastoma is a significant milestone in the fight against one of the most aggressive cancers. As we advance, it is imperative that we continue to innovate, research, and advocate for therapies that can transform the landscape of cancer treatment. Ethical approval Ethical approval is not applicable for this correspondence article. Consent Informed consent is not applicable for this correspondence article. Sources of funding Not applicable. Author contribution A.A.: conceptualization, project administration, supervision, validation, visualization, writing –original draft, and writing – review and editing; N.A.W.: project administration, validation, visualization, writing – original draft, and writing – review and editing; P.S. and R.K.S.: supervision, validation, and writing – review and editing; D.S., M.A., M.N.K., S.G., Q.S.Z., and S.R.: supervision, validation, and writing – review and editing. Conflicts of interest disclosure No conflict of interest to declare. Research registration unique identifying number (UIN) Not applicable. Guarantor Ayush Anand. Data availability statement Not applicable. Provenance and peer review Not commissioned, externally peer-reviewed.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».